Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
About this item
Full title
Author / Creator
Golan, Talia , Hammel, Pascal , Reni, Michele , Van Cutsem, Eric , Macarulla, Teresa , Hall, Michael J , Park, Joon-Oh , Hochhauser, Daniel , Arnold, Dirk , Oh, Do-Youn , Reinacher-Schick, Anke , Tortora, Giampaolo , Algül, Hana , O’Reilly, Eileen M , McGuinness, David , Cui, Karen Y , Schlienger, Katia , Locker, Gershon Y and Kindler, Hedy L
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Approximately 7% of pancreatic cancers occur in patients with a germline mutation in
BRCA1
or
BRCA2
, an alteration that compromises DNA repair. In a randomized trial in patients with metastatic pancreatic cancer that had responded to platinum-based chemotherapy, progression-free survival was nearly twice as long with olaparib than with...
Alternative Titles
Full title
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Authors, Artists and Contributors
Author / Creator
Hammel, Pascal
Reni, Michele
Van Cutsem, Eric
Macarulla, Teresa
Hall, Michael J
Park, Joon-Oh
Hochhauser, Daniel
Arnold, Dirk
Oh, Do-Youn
Reinacher-Schick, Anke
Tortora, Giampaolo
Algül, Hana
O’Reilly, Eileen M
McGuinness, David
Cui, Karen Y
Schlienger, Katia
Locker, Gershon Y
Kindler, Hedy L
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6810605
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6810605
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1903387
